Pneumonia: Types, Causes, and Complications

Pneumonia is an acute infection of the lung parenchyma that inflames the air sacs (alveoli), causing them to fill with fluid or pus and impairing gas exchange. It ranks among the most common causes of infection-related hospitalization in the United States and represents a leading source of respiratory morbidity across all age groups. This page covers the major classification systems for pneumonia, the biological mechanisms driving lung damage, the populations and clinical settings most affected, and the diagnostic and severity boundaries that guide clinical decision-making.

Definition and Scope

Pneumonia is formally defined by the Centers for Disease Control and Prevention (CDC) as an infection that inflames the air sacs in one or both lungs. The CDC lists pneumonia as a condition responsible for more than 1.5 million emergency department visits annually in the United States, making it a significant burden on the acute care system.

Classification of pneumonia follows two primary frameworks: etiological (causative organism) and epidemiological (where and how the infection was acquired). The epidemiological framework has direct implications for treatment selection because the likely pathogen profile differs substantially depending on acquisition setting. The /regulatory-context-for-pulmonary page details how federal and accrediting bodies classify pulmonary conditions for coding, quality reporting, and reimbursement purposes — categories that directly affect how pneumonia cases are documented in clinical practice.

Major Classification Types

1. Community-Acquired Pneumonia (CAP)
Acquired outside a healthcare facility or within 48 hours of hospital admission. The most common causative organism in CAP is Streptococcus pneumoniae (pneumococcal pneumonia). The Infectious Diseases Society of America (IDSA) and American Thoracic Society (ATS) jointly maintain clinical practice guidelines for CAP that define diagnostic criteria and severity stratification.

2. Hospital-Acquired Pneumonia (HAP)
Develops 48 or more hours after hospital admission and was not incubating at the time of admission. HAP pathogens frequently include gram-negative bacilli and Staphylococcus aureus, including methicillin-resistant strains (MRSA).

3. Ventilator-Associated Pneumonia (VAP)
A subtype of HAP occurring in patients who have been on mechanical ventilation for more than 48 hours. VAP is a nationally tracked healthcare-associated infection (HAI); the National Healthcare Safety Network (NHSN), operated by the CDC, requires hospitals to report VAP events as a condition of participation in federal quality programs.

4. Aspiration Pneumonia
Caused by inhalation of oropharyngeal or gastric contents. This type disproportionately affects patients with dysphagia, altered consciousness, or impaired gag reflexes.

5. Atypical Pneumonia
Caused by organisms such as Mycoplasma pneumoniae, Chlamydophila pneumoniae, or Legionella pneumophila. Atypical pneumonias often present with more gradual onset and extrapulmonary symptoms; Legionella is a reportable condition under the National Notifiable Diseases Surveillance System (NNDSS).

How It Works

Pneumonia begins when a pathogen — bacterial, viral, fungal, or parasitic — overcomes the respiratory tract's defense mechanisms and establishes infection in the lower airways or alveolar tissue.

The pathophysiological sequence proceeds in recognizable phases:

1. Congestion: Vascular engorgement and alveolar edema develop within the first 24 hours as the immune system responds. Fluid floods the alveoli, reducing their capacity for gas exchange.
2. Red hepatization: Fibrin, erythrocytes, and neutrophils consolidate in the alveolar spaces. The lung tissue becomes firm and liver-like in texture, typically by day 2–3.
3. Grey hepatization: Erythrocytes lyse; the alveoli remain packed with fibrin and leukocytes. Macrophages begin clearing debris.
4. Resolution: Enzymatic digestion of fibrin clears alveolar spaces; normal lung architecture is typically restored in uncomplicated cases within 2–4 weeks.

The primary physiological consequence is ventilation-perfusion (V/Q) mismatch: alveoli that receive blood flow cannot participate in gas exchange because they are filled with exudate, producing hypoxemia. The degree of hypoxemia correlates with the extent of lung involvement, which is why bilateral or multilobar pneumonia carries higher mortality than single-lobe disease.

Viral pneumonia, most commonly caused by influenza viruses or SARS-CoV-2, follows a somewhat different course: the virus directly injures type II pneumocytes, disrupts surfactant production, and can trigger a cytokine-mediated inflammatory cascade that progresses to acute respiratory distress syndrome (ARDS) in severe cases.

Common Scenarios

Pneumonia does not affect all populations equally. Several host and environmental factors concentrate risk:

• Age extremes: Adults aged 65 and older and children under 5 face disproportionate severity. The CDC Advisory Committee on Immunization Practices (ACIP) recommends pneumococcal vaccination for both groups on the basis of this elevated risk.
• Immunocompromised hosts: Patients receiving chemotherapy, those with HIV infection, and solid organ transplant recipients are susceptible to opportunistic organisms such as Pneumocystis jirovecii (PCP), which rarely causes disease in immunocompetent individuals.
• Chronic lung disease: Individuals with COPD, bronchiectasis, or pulmonary fibrosis have structurally compromised airways that increase susceptibility to bacterial colonization and infection.
• Institutional settings: Nursing facility residents face pathogen exposures and functional limitations — including swallowing dysfunction — that elevate both aspiration and healthcare-associated pneumonia risk.
• Occupational exposure: Certain inhaled occupational agents predispose to specific pneumonia types; the National Institute for Occupational Safety and Health (NIOSH) catalogues lung disease risks by industry, including pneumoconioses that can impair pulmonary defenses. See also occupational lung disease for a detailed breakdown.

Diagnostic workup typically begins with a chest X-ray to confirm the presence and extent of consolidation, with CT imaging of the chest reserved for equivocal cases or suspected complications. Microbiological confirmation via sputum testing or bronchoscopy guides pathogen-directed therapy, particularly in hospitalized or critically ill patients.

Decision Boundaries

Determining the appropriate level of care is one of the most consequential clinical decisions in pneumonia management. Two validated scoring tools define the evidence base for this decision:

Pneumonia Severity Index (PSI) — Developed from the Pneumonia Patient Outcomes Research Team (PORT) study, the PSI stratifies patients into five risk classes based on 20 variables including age, comorbidities, vital signs, and laboratory findings. Classes I–III correspond to outpatient management; classes IV–V indicate hospitalization.

CURB-65 Score — Endorsed in IDSA/ATS guidelines, this 5-point scale assesses Confusion, elevated Blood Urea Nitrogen (>19 mg/dL), Respiratory rate (≥30 breaths/min), low Blood pressure (systolic <90 mmHg or diastolic ≤60 mmHg), and age ≥65. A score of 0–1 supports outpatient treatment; a score of 3 or higher signals consideration of ICU-level care.

CAP vs. HAP: A Key Clinical Contrast

Major Complications

Failure to achieve clinical resolution raises concern for:

1. Parapneumonic effusion and empyema — Fluid accumulating in the pleural space; thoracentesis is both diagnostic and therapeutic. See pleural effusion for mechanism details.
2. Lung abscess — Necrotic cavitation within consolidated lung tissue, most commonly associated with aspiration or anaerobic organisms.
3. Bacteremia and sepsis — S. pneumoniae bacteremia complicates 25–30% of hospitalized pneumococcal pneumonia cases (IDSA Clinical Practice Guidelines).
4. Acute Respiratory Distress Syndrome (ARDS) — Severe bilateral pneumonia can progress to ARDS, a condition defined by the Berlin Definition (published in JAMA, 2012) as acute-onset hypoxemia with bilateral opacities not fully explained by cardiac failure.
5. Post-infectious complications — Organizing pneumonia and fibrotic scarring can persist after acute infection resolves, requiring

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)